- Conditions
- TTR-mediated Amyloidosis
- Interventions
- Revusiran (ALN-TTRSC)
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York • Cleveland, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hypertrophic Cardiomyopathy, Left Ventricular Hypertrophy
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Myocardial Ischemia, Congestive Heart Failure, Cardiovascular Disease
- Interventions
- Intramyocardial injection of autologous CD34-positive cells (stem cells)
- Biological
- Lead sponsor
- Losordo, Douglas, M.D.
- Individual
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Cardiomyopathy, Hypertrophic, Coronary Disease, Healthy, Myocardial Ischemia, Syndrome X
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1995 – 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Heart Failure With Reduced Ejection Fraction, Nonischemic Cardiomyopathy
- Interventions
- Not listed
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- LGMD1B, LGMD1C, LGMD1D, LGMD1E, LGMD1F, LGMD1G, LGMD1H, LGMD2A, LGMD2B, LGMD2C, LGMD2D, LGMD2E, LGMD2F, LGMD2G, LGMD2I, LGMD2J, LGMD2K, LGMD2L, LGMD2M, LGMD2N, LGMD2O, LGMD2P, LGMD2Q, LGMD2S, LGMD2T, LGMD2U, LGMD2W, LGMD2X, LGMD2Y
- Interventions
- Not listed
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 6 Years to 50 Years
- Enrollment
- 1,000 participants
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Ischemic Heart Disease, Non-ischemic Cardiomyopathy
- Interventions
- Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC), Placebo
- Biological · Other
- Lead sponsor
- Medstar Health Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Metabolic Disease, Obesity, Li-Fraumeni Syndrome, Cardiomyopathy, Atherosclerosis, Inflammatory Disease
- Interventions
- NSR IDE-MRI: Research pulse sequences
- Device
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 1 Year to 100 Years
- Enrollment
- 5,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2010
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Bethesda, Maryland
- Conditions
- Apical Ballooning Syndrome
- Interventions
- PET scan
- Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Heart Failure, Vitamin D Deficiency, Cardiomyopathy, Congestive Heart Failure
- Interventions
- Placebo Comparator: Sugar Pill, Vitamin D3 (cholecalciferol)
- Drug
- Lead sponsor
- Heidi Moretti, MS, RD
- Other
- Eligibility
- Not listed
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 2
- States / cities
- Missoula, Montana
- Conditions
- Cardiomyopathy, Arrhythmia, Muscular Dystrophy
- Interventions
- Blood draw (genetic testing)
- Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- Not listed
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2030
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Obstructive Hypertrophic Cardiomyopathy
- Interventions
- Mavacamten
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Ischemic Cardiomyopathy, Non-ischemic Cardiomyopathy, Heart Failure, Cardiomyopathies
- Interventions
- AAV1/SERCA2a (MYDICAR), Placebo
- Genetic
- Lead sponsor
- Celladon Corporation
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more
- Conditions
- Autoimmune Diseases, Cardiovascular Disorders, Diabetes Complications, Integumentary Disease, Musculoskeletal Disorders, Neurodegenerative Disorders, Neurologic Disorders, Pulmonary Disorders, Sexual Dysfunction, Urologic Disorders, Viral Illness
- Interventions
- PrimePro™/ PrimeMSK™
- Biological
- Lead sponsor
- Thomas Advanced Medical LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2030
- U.S. locations
- 1
- States / cities
- Culver City, California
- Conditions
- Familial Amyloidotic Cardiomyopathy (FAC)
- Interventions
- Not listed
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,010 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 43
- States / cities
- Little Rock, Arkansas • Bakersfield, California • La Mesa, California + 32 more
- Conditions
- Cardiomyopathy, Pregnancy-Associated Cardiomyopathy, Heart Failure
- Interventions
- Not listed
- Lead sponsor
- St. Vincent's Medical Center
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Sickle Cell Disease
- Interventions
- Deferoxamine, Deferasirox, Deferiprone, Echocardiography, Electrocardiogram (ECG)
- Drug · Device
- Lead sponsor
- Inova Health Care Services
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Fairfax, Virginia • Falls Church, Virginia
- Conditions
- Duchenne Muscular Dystrophy (DMD)
- Interventions
- SGLT-2 inhibitor, SGLT2 inhibitor
- Drug
- Lead sponsor
- Larry W. Markham
- Other
- Eligibility
- 8 Years to 18 Years · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Symptomatic Hypertrophic Cardiomyopathy (HCM)
- Interventions
- Aficamten (5 - 20 mg)
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 39 more
- Conditions
- DMD-Associated Dilated Cardiomyopathy
- Interventions
- SRD-001
- Genetic
- Lead sponsor
- Sardocor Corp.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 3
- States / cities
- Kansas City, Kansas • Cincinnati, Ohio • Columbus, Ohio
- Conditions
- Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies, Heart Diseases
- Interventions
- acoramidis, Placebo Oral Tablet
- Drug
- Lead sponsor
- Eidos Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 632 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 40
- States / cities
- Los Angeles, California • Santa Monica, California • Aurora, Colorado + 32 more
- Conditions
- Ischemic Stroke, Ischemia, Atrial Fibrillation, Transient Ischemic Attack, Transient Cerebrovascular Events, Thrombotic Stroke, Stroke, Stroke, Acute, Stroke, Ischemic, Stroke, Complication, Stroke of Basilar Artery, Atherosclerosis, Atheroma, Cardioembolic Stroke, Cardiomyopathies, Cardiovascular Stroke, Thromboembolism
- Interventions
- ISCDX blood test
- Diagnostic Test
- Lead sponsor
- Ischemia Care LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Non-ischemic Dilated Cardiomyopathy
- Interventions
- Autologous hMSCs, Allogeneic hMSCs
- Biological
- Lead sponsor
- Joshua M Hare
- Other
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Idiopathic Dilated Cardiomyopathy
- Interventions
- Carvedilol, Metoprolol succinate, Metoprolol succinate + doxazosin
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2009
- U.S. locations
- 2
- States / cities
- Denver, Colorado • Salt Lake City, Utah